Reverse immunology approach for the identification of CD8 T-cell-defined antigens: advantages and hurdles.

Détails

ID Serval
serval:BIB_507A48156F4D
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Reverse immunology approach for the identification of CD8 T-cell-defined antigens: advantages and hurdles.
Périodique
Immunology and cell biology
Auteur(s)
Viatte S., Alves P.M., Romero P.
ISSN
0818-9641
Statut éditorial
Publié
Date de publication
2006
Peer-reviewed
Oui
Volume
84
Numéro
3
Pages
318-330
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
One of the challenges of tumour immunology remains the identification of strongly immunogenic tumour antigens for vaccination. Reverse immunology, that is, the procedure to predict and identify immunogenic peptides from the sequence of a gene product of interest, has been postulated to be a particularly efficient, high-throughput approach for tumour antigen discovery. Over one decade after this concept was born, we discuss the reverse immunology approach in terms of costs and efficacy: data mining with bioinformatic algorithms, molecular methods to identify tumour-specific transcripts, prediction and determination of proteasomal cleavage sites, peptide-binding prediction to HLA molecules and experimental validation, assessment of the in vitro and in vivo immunogenic potential of selected peptide antigens, isolation of specific cytolytic T lymphocyte clones and final validation in functional assays of tumour cell recognition. We conclude that the overall low sensitivity and yield of every prediction step often requires a compensatory up-scaling of the initial number of candidate sequences to be screened, rendering reverse immunology an unexpectedly complex approach.
Mots-clé
Antigens, Neoplasm/immunology, CD8-Positive T-Lymphocytes/immunology, Humans, Immunotherapy, Neoplasms/immunology, Neoplasms/therapy, T-Lymphocytes, Cytotoxic/immunology
Pubmed
Web of science
Création de la notice
28/01/2008 12:27
Dernière modification de la notice
03/03/2018 17:09
Données d'usage